Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile
Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology
https://finance.yahoo.com/news/jazz-pharmaceuticals-reports-clinically-meaningful-163500150.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.